Immix Biopharma, Inc. develops clinical-stage cell therapies focused on relapsed/refractory AL Amyloidosis, led by NXC-201, a sterically optimized BCMA-targeted CAR-T therapy. Company news commonly covers NXC-201 clinical data from the NEXICART-2 study, FDA designations such as Breakthrough Therapy, RMAT and orphan-drug status, and regulatory-development planning.
Updates also include equity financings, pre-funded warrants, private placements, investor-conference participation, and commercial and medical leadership additions tied to the company’s rare-disease oncology and hematology strategy.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.